PE20231076A1 - Anticuerpos anti-pd-1 - Google Patents
Anticuerpos anti-pd-1Info
- Publication number
- PE20231076A1 PE20231076A1 PE2022002742A PE2022002742A PE20231076A1 PE 20231076 A1 PE20231076 A1 PE 20231076A1 PE 2022002742 A PE2022002742 A PE 2022002742A PE 2022002742 A PE2022002742 A PE 2022002742A PE 20231076 A1 PE20231076 A1 PE 20231076A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- antibodies
- cdr1
- cdr3
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Refiere a nuevos anticuerpos anti-PD-1 (muerte celular programada 1) y fragmentos de union al antigeno de los mismos, que comprenden una region variable de la cadena pesada con las secuencias de aminoacidos SEQ ID NO: 43 (H-CDR1), SEQ ID NO: 44 (H-CDR12) o SEQ ID NO: 45 (H-CDR3); y una region variable de la cadena ligera con las secuencias SEQ ID NO: 1 (L-CDR1), SEQ ID NO: 2 (L-CDR2) o SEQ ID NO: 3 (L-CDR3). Ambas regiones tienen un 90%-99% de afinidad con las secuencias SEQ ID NO: 131 y SEQ ID NO: 135. Asimismo, dichos anticuerpos y fragmentos de union a antigeno comprenden una region constante de la cadena pesada de una IgG1 con las mutaciones Leu234Ala y Leu235Ala, y una region constante de la cadena ligera seleccionada de kappa y lambda. Tambien, la presente menciona una composicion farmaceutica a base de los mismos junto a un excipiente farmaceuticamente aceptable, para usarse en el tratamiento de enfermedades derivadas del trastorno de la via PD-1, como esclerosis sistemica (SSc), metodos para el tratamiento de los trastornos y para la elaboracion de la composicion farmaceutica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063029962P | 2020-05-26 | 2020-05-26 | |
| US202063039686P | 2020-06-16 | 2020-06-16 | |
| PCT/US2021/033823 WO2021242663A1 (en) | 2020-05-26 | 2021-05-24 | Anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231076A1 true PE20231076A1 (es) | 2023-07-17 |
Family
ID=76808128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002742A PE20231076A1 (es) | 2020-05-26 | 2021-05-24 | Anticuerpos anti-pd-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20210380696A1 (es) |
| EP (2) | EP4464383A3 (es) |
| JP (2) | JP7512433B2 (es) |
| KR (1) | KR20230015997A (es) |
| CN (1) | CN115956087A (es) |
| AU (1) | AU2021280232A1 (es) |
| BR (1) | BR112022023989A2 (es) |
| CA (1) | CA3181776A1 (es) |
| CL (1) | CL2022003304A1 (es) |
| CO (1) | CO2022018416A2 (es) |
| CR (1) | CR20220596A (es) |
| DK (1) | DK4157876T3 (es) |
| DO (1) | DOP2022000264A (es) |
| EC (1) | ECSP22092185A (es) |
| ES (1) | ES2994127T3 (es) |
| FI (1) | FI4157876T3 (es) |
| HR (1) | HRP20241488T1 (es) |
| HU (1) | HUE069403T2 (es) |
| IL (1) | IL298431A (es) |
| LT (1) | LT4157876T (es) |
| MA (1) | MA59827B1 (es) |
| MX (1) | MX2022014974A (es) |
| PE (1) | PE20231076A1 (es) |
| PH (1) | PH12022553181A1 (es) |
| PL (1) | PL4157876T3 (es) |
| PT (1) | PT4157876T (es) |
| RS (1) | RS66193B1 (es) |
| SI (1) | SI4157876T1 (es) |
| TW (1) | TWI859446B (es) |
| WO (1) | WO2021242663A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US266710A (en) | 1882-10-31 | Fastening for pocket-books | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2005211725B2 (en) | 2004-02-09 | 2010-07-15 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| MX344595B (es) | 2010-12-31 | 2016-12-20 | Bioatla Llc | Humanizacion rapida de anticuerpos. |
| CN105330740B (zh) * | 2014-07-30 | 2018-08-17 | 珠海市丽珠单抗生物技术有限公司 | 抗pd-1抗体及其应用 |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| JP7105238B2 (ja) * | 2017-01-18 | 2022-07-22 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１抗体に対するイディオタイプ抗体及びそれらの使用 |
| CR20190550A (es) | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
| TWI708787B (zh) | 2018-03-02 | 2020-11-01 | 美商美國禮來大藥廠 | Pd-1促效劑抗體及其用途 |
| CN113861295B (zh) * | 2018-07-20 | 2024-05-24 | 厦门大学 | 抗pd-1抗体及其用途 |
| MX2021015054A (es) | 2019-06-05 | 2022-03-17 | Anaptysbio Inc | Agonista de pd-1 y metodo para usar el mismo. |
-
2021
- 2021-05-24 TW TW110118624A patent/TWI859446B/zh active
- 2021-05-24 CR CR20220596A patent/CR20220596A/es unknown
- 2021-05-24 IL IL298431A patent/IL298431A/en unknown
- 2021-05-24 PE PE2022002742A patent/PE20231076A1/es unknown
- 2021-05-24 KR KR1020227045536A patent/KR20230015997A/ko active Pending
- 2021-05-24 US US17/328,050 patent/US20210380696A1/en active Pending
- 2021-05-24 JP JP2022572362A patent/JP7512433B2/ja active Active
- 2021-05-24 PT PT217391978T patent/PT4157876T/pt unknown
- 2021-05-24 CA CA3181776A patent/CA3181776A1/en active Pending
- 2021-05-24 PL PL21739197.8T patent/PL4157876T3/pl unknown
- 2021-05-24 WO PCT/US2021/033823 patent/WO2021242663A1/en active Application Filing
- 2021-05-24 RS RS20241278A patent/RS66193B1/sr unknown
- 2021-05-24 ES ES21739197T patent/ES2994127T3/es active Active
- 2021-05-24 MX MX2022014974A patent/MX2022014974A/es unknown
- 2021-05-24 BR BR112022023989A patent/BR112022023989A2/pt unknown
- 2021-05-24 LT LTEPPCT/US2021/033823T patent/LT4157876T/lt unknown
- 2021-05-24 FI FIEP21739197.8T patent/FI4157876T3/fi active
- 2021-05-24 PH PH1/2022/553181A patent/PH12022553181A1/en unknown
- 2021-05-24 HU HUE21739197A patent/HUE069403T2/hu unknown
- 2021-05-24 MA MA59827A patent/MA59827B1/fr unknown
- 2021-05-24 EP EP24193396.9A patent/EP4464383A3/en active Pending
- 2021-05-24 HR HRP20241488TT patent/HRP20241488T1/hr unknown
- 2021-05-24 SI SI202130213T patent/SI4157876T1/sl unknown
- 2021-05-24 CN CN202180037658.8A patent/CN115956087A/zh active Pending
- 2021-05-24 AU AU2021280232A patent/AU2021280232A1/en active Pending
- 2021-05-24 EP EP21739197.8A patent/EP4157876B1/en active Active
- 2021-05-24 DK DK21739197.8T patent/DK4157876T3/da active
-
2022
- 2022-11-23 DO DO2022000264A patent/DOP2022000264A/es unknown
- 2022-11-24 CL CL2022003304A patent/CL2022003304A1/es unknown
- 2022-12-09 EC ECSENADI202292185A patent/ECSP22092185A/es unknown
- 2022-12-19 CO CONC2022/0018416A patent/CO2022018416A2/es unknown
-
2024
- 2024-06-26 JP JP2024102704A patent/JP2024125366A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| RU2019132843A (ru) | Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| NZ723369A (en) | Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema | |
| SI2579894T1 (en) | CGRP PROTITELESA | |
| PE20080112A1 (es) | Anticuerpo humanizado especifico para tslp (linfopoyetina estromal timica) y composiciones farmaceuticas | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| AR102594A1 (es) | ANTICUERPOS ANTI-IL-1b Y MÉTODOS DE USO | |
| RU2014139552A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| EA032189B9 (ru) | Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их | |
| AR105978A1 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp) y métodos de uso de las moléculas | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| BR112018002436A2 (pt) | tratamento de combinação de usos de métodos destes | |
| RU2017144629A (ru) | Тромбин-связывающие молекулы антител и их применение | |
| HRP20191293T1 (hr) | Anti-transglutaminaza 2 antitijela | |
| AR123671A1 (es) | Anticuerpo fn14 anti-humano | |
| RU2014117952A (ru) | Антитела против sema4a человека, используемые для лечения заболевания | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний |